20 articles
A comprehensive 2025 review maps the mechanisms, sources, and clinical applications of mesenchymal stem cells and their derived exosomes across cardiovascular, neurological, autoimmune, and musculoskeletal diseases.
65-patient trial tested bone marrow stem cells injected directly into damaged heart muscle to restore function in chronic heart failure.
Scientists created modified stem cells that home to bone marrow, delivering targeted immune therapies while avoiding tumors entirely.
Researchers compared stem cells from arthritis patients versus healthy donors to assess regenerative therapy potential.
Adipose-derived stem cells combined with platelet-rich plasma evaluated for treating moderate to severe knee osteoarthritis over 2 years.
32-person trial compared bone marrow stem cells, platelet therapy, and hyaluronic acid for knee arthritis treatment over one year.
Tiny particles from stem cells could deliver therapeutic benefits without the risks of traditional cell-based treatments.
Combining nanoparticles with mesenchymal stem cells could finally overcome the poor survival and differentiation that limits cartilage regeneration.
Small trial tests autologous stem cells to regenerate damaged knee cartilage in osteoarthritis patients with promising safety profile.
Scientists explore safer alternatives to stem cell transplants using cellular secretions that may offer similar benefits.
A comprehensive review maps how mesenchymal stem cells and their exosomes combat Alzheimer's, atherosclerosis, osteoporosis, and ovarian failure.
Analysis of 449 clinical trials reveals mesenchymal stem cells are leading treatment for osteoarthritis and rheumatoid arthritis worldwide.
Autologous stem cell injections tested in patients with severe leg circulation problems who had no surgical options.
NIDCR researchers compared stromal cells from bone marrow, skin, spleen, and fat to identify which best regenerates bone and supports blood formation.
A Phase 1/2 trial tests four rounds of intrathecal MSC injections in ALS patients, targeting both safety and disease progression.
A phase 2b trial finds allogeneic MSC infusions improved 6-minute walk distance by 63 meters vs placebo at 9 months in frail older adults.
New research reveals how tiny cellular packages from stem cells could revolutionize treatment for this devastating muscle disease.
Dual stem cell therapy from fat tissue dramatically reduces limb amputation risk by rebuilding blood vessels in severe circulation disease.
A comprehensive review of cell-based therapies and engineered biomaterials for SCI, covering ESCs, MSCs, NSCs, and scaffold strategies.
New delivery systems dramatically improve stem cell survival and therapeutic effectiveness in tissue repair applications.
